orphan drugs
CRO market growing steadily but global shifts expected
December 11 by Natasha TaylorLatest report predicts that blockbuster M&As will raise capabilities, but might not be enough to stop companies looking to emerging markets.
Pharmaceutical Companies Increasingly Adopting Orphans
August 09 by Pharma IQOrphan diseases had been traditionally neglected. By their definition, they were often rare and so it was not financial sound to pursue developing a treatment for them. In 1983 however, the US gover...
The Boardroom Series: Interview with Orphazyme's CMO Carlos Camozzi Full Interview
June 03 by Pharmaceuticals & Biotechnology EditorDr Carlos Camozzi is the new Chief Medical Officer at the Biotech Company Orphazyme, located in Denmark. Carlos has over 25 years in clinical research and development roles in pharma and biotech com...
Orphan Diseases - Living with Ataxia’s Nightmare in the Land of Innovation
November 30 by Cristina FalcãoThe patient is the most important stakeholder in healthcare. Every day patients are questioning their treatment options and making product choices through their own research. With orphan d...
Orphan Drugs – Reinventing Economies of Scale
November 16 by Cristina FalcãoEconomies of scale come in many flavors. Including the oddity flavor where the number of manufactured products decreases and the size of markets shrink. Orphan drugs are economies of scale’...
Orphan Drugs are Forerunners of Personalised Medicine
October 20 by Cristina FalcãoMarketing exclusivity in EU and U.S.A provided a monopolistic market for orphan drugs without “me-too”/generics competitors, to pharma companies. Orphan drug laws and the pharma indus...
Are Orphan Disease Areas Orphaned?
August 02 by Pharma IQ NewsLeading biopharmaceutical research consultancy Medical Marketing Research Group (MMR Group) has successfully completed two major orphan drug Opinion Leader identification projects for two of the wor...
Are Orphan Drugs Still a Licence to Print Money?
July 20 by Andrea CharlesIn this podcast Donald Macarthur, global pharmaceutical business analyst, speaks to Andrea Charles from Pharma IQ, about Pharma's steps into the orphan drug market and whether payers can afford to fun...
Renewed Realisation of Orphan Drug Market Potential
December 08 by Pharma IQOrphan drugs were previously considered not worthwhile for development by pharmaceutical companies due to their small patient base, which was translated by some to mean small revenues. Orphan buz...
The Boardroom Series: Interview with Orphazyme's CMO Carlos Camozzi
March 29 by Carlos CamozziDr Carlos Camozzi is the new Chief Medical Officer at the Biotech Company Orphazyme, located in Denmark. Carlos has over 25 years in clinical research and development roles in pharma and biotech compa...